RFX6-mediated dysregulation defines human β cell dysfunction in early type 2 diabetes

John T. Walker(Vanderbilt University), Marcela Briššová(Vanderbilt University Medical Center), Samir Agarwala(University of Michigan), Dale L. Greiner(University of Massachusetts Chan Medical School), Simin Fan(Guangzhou University of Chinese Medicine), Yasminye D. Pettway(Vanderbilt University), Conrad Reihsmann(Vanderbilt University Medical Center), Nathaniel Hart(Vanderbilt University Medical Center), Alexander L. Hopkirk(Vanderbilt University Medical Center), Leonard D. Shultz(Jackson Laboratory), Vivek Rai(University of Michigan), Alvin C. Powers(Vanderbilt University Medical Center), Yicheng Tao(University of Michigan), Chunhua Dai(Diabetes Australia), Peter Orchard(University of Michigan), Rita Bottino(Children's Hospital of Pittsburgh), Stephen C.J. Parker(Unknown), Greg Poffenberger(Vanderbilt University Medical Center), Diane C. Saunders(Vanderbilt University Medical Center), Shristi Shrestha(Vanderbilt University), Christa Ventresca(University of Michigan), Jie Liu(University of Michigan), J. J. Wright(Vanderbilt University Medical Center), Regina Jenkins(Vanderbilt University Medical Center), Radhika Aramandla(Vanderbilt University Medical Center), Arushi Varshney(University of Michigan)
bioRxiv (Cold Spring Harbor Laboratory)
December 17, 2021
Cited by 9


Related Papers